This study is for people with non-small cell lung cancer (NSCLC) that has spread to the brain. Researchers are testing the safety of a drug called ivonescimab when given with chemotherapy and stereotactic radiosurgery (SRS), a type of radiation therapy. They will start with a dose of 10 mg/kg of ivonescimab and may increase it to 15 mg/kg or 20 mg/kg. The goal is to find the safest dose that causes few side effects. Once the best dose is found, they will then see how well it treats the brain metastases. To join, you must have NSCLC, at least one brain tumor between 1.0 cm and 3.5 cm, and your PD-L1 tumor score must be known. The study aims to identify the best dose within 21 days and then measure how long people live without their brain tumors growing for at least 3 months.

Study design

This is an interventional study planning to enroll 53 participants. It is testing different doses of ivonescimab in combination with chemotherapy and radiation.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how long people live without their brain tumors growing for at least 3 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.